ID   KT-1 [Human leukemia]
AC   CVCL_D200
SY   KT1
DR   EFO; EFO_0022545
DR   Wikidata; Q54900516
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9427720;
RX   PubMed=10071072;
RX   PubMed=11111114;
CC   Population: Japanese.
CC   Characteristics: Sensitive to the antiproliferative and apoptosis-inducing effects of IFN-alpha.
CC   Doubling time: 18-24 hours (PubMed=9427720).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9427720; PubMed=10071072).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C3174; Chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   32Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 17
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=9427720; DOI=10.1182/blood.V91.2.641;
RA   Yanagisawa K., Yamauchi H., Kaneko M., Kohno H., Hasegawa H.,
RA   Fujita S.;
RT   "Suppression of cell proliferation and the expression of a bcr-abl
RT   fusion gene and apoptotic cell death in a new human chronic
RT   myelogenous leukemia cell line, KT-1, by interferon-alpha.";
RL   Blood 91:641-648(1998).
//
RX   PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4;
RA   Drexler H.G., MacLeod R.A.F., Uphoff C.C.;
RT   "Leukemia cell lines: in vitro models for the study of Philadelphia
RT   chromosome-positive leukemia.";
RL   Leuk. Res. 23:207-215(1999).
//
RX   PubMed=11111114; DOI=10.1159/000041061;
RA   Yamauchi H., Sakai I., Narumi H., Soga S., Fujita S.;
RT   "Sensitivity to interferon-alpha and interferon-stimulated gene factor
RT   3 binding activity in human chronic myelogenous leukemia cell line
RT   KT-1.";
RL   Acta Haematol. 104:1-9(2000).
//